<DOC>
	<DOCNO>NCT01745458</DOCNO>
	<brief_summary>This study design ass whether inhibition plasma Lp-PLA2 activity impact platelet function assess ex vivo platelet aggregation test vivo plasma biomarkers .</brief_summary>
	<brief_title>SB-659032 Platelet Aggregation Study</brief_title>
	<detailed_description>SB-659032 selective orally active inhibitor lipoprotein-associated phospholipase A2 ( Lp-PLA2 ) develop treatment atherosclerosis . This study design ass whether inhibition plasma Lp-PLA2 activity impact platelet function assess ex vivo platelet aggregation test vivo plasma biomarkers . Blood sample PK analysis measurement Lp-PLA2 activity also collect . Questionnaires complete evaluate frequency odorrelated AEs non-enteric coated formulation SB-659032 relative placebo . This double blind , repeat dose , randomize , placebo-controlled , two period , period balance , crossover study . There minimum 21 day washout period dose period .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Healthy adult male 18 55 year age , inclusive Body weight great 50 kg ( 110 pound ) body mass index ( BMI ) 19 32 : BMI = weight kg/ ( height meter ) 2 A sign date write informed consent prior admission study The subject able understand comply protocol requirement , instruction protocolstated restriction . Any clinically relevant abnormality identify screen medical assessment , laboratory examination ECG Platelet count reference range History hypercoagulable state history thrombosis History platelet dysfunction A known history Gilbert 's Syndrome History asthma , anaphylaxis anaphalactoid reaction , severe allergic responses A history alcohol , substance drug abuse within last year positive alcohol breath test screen predose period . Abuse alcohol define average weekly intake great equal 21 unit ( male ) average daily intake great equal 3 unit ( male ) . 1 unit equivalent 285mL glass full strength beer 425 mL schooner light beer 1 ( 30 mL ) measure spirit 1 glass ( 100 mL ) wine Positive urine drug screen screen predose period History use tobacco nicotine containing product within 6 month screen positive urine cotinine screen exhaled carbon monoxide test predose period Positive HIV , Hepatitis B Hepatitis C screen Use aspirin , aspirincontaining product , nonsteroidal antiinflammatory agent antiplatelet medication within 14 day prior Day 1 study ( list drug review subject screening provide take home ) Use prescription ( include hormone replacement therapy ) nonprescription drug vitamin within 7 day 5 halflives ( whichever longer ) prior Day 1 study . An exception acetaminophen allow dos â‰¤ 2g/day Use dietary/herbal supplement include ( limited ) St. John 's wort , kava , ephedra ( huang ) , gingko biloba , DHEA , yohimbe , saw palmetto , ginseng red yeast rice within 14 day prior Day 1 study Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose Consumption grapefruit grapefruit juice within 7 day prior Day 1 study A history cholecystectomy biliary tract disease include history liver disease elevate liver function test know unknown etiology An unwillingness abstain sexual intercourse pregnant lactate woman unwillingness use condom another form contraception ( e.g. , IUD , birth control pills take female partner , diaphragm spermicide ) engage sexual intercourse woman could become pregnant discharge study Donation blood excess 500 mL within 56 day donation blood excess 250 mL within 7 day prior dose Full ADP and/or collageninduced aggregation ( great equal 40 % ) three concentration one agonist , assess within 6 month prior first dose Day 1 period No ADP collageninduced aggregation ( le 40 % ) high concentration either agonist , assess within 6 month prior first dose Day 1 period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>